IRIS
CRISCUOLO, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 384
NA - Nord America 305
AS - Asia 164
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
SA - Sud America 1
Totale 865
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 305
SE - Svezia 188
IT - Italia 109
CN - Cina 92
SG - Singapore 63
RU - Federazione Russa 47
FI - Finlandia 17
IE - Irlanda 9
DE - Germania 7
IN - India 4
AU - Australia 3
CM - Camerun 3
A1 - Anonimo 2
HK - Hong Kong 2
PH - Filippine 2
PL - Polonia 2
BR - Brasile 1
DK - Danimarca 1
EU - Europa 1
FR - Francia 1
GB - Regno Unito 1
KR - Corea 1
MA - Marocco 1
NL - Olanda 1
RO - Romania 1
ZA - Sudafrica 1
Totale 865
Salva come PNG Salva come JPEG
Città #
Ashburn 75
Milan 68
Princeton 39
Shanghai 39
Lawrence 38
Singapore 36
New York 26
Moscow 19
Helsinki 15
Dublin 9
Guangzhou 7
Rome 7
Boardman 5
Los Angeles 5
Ancona 4
Pune 4
Santa Clara 4
Shenzhen 4
South San Francisco 4
Turin 4
Washington 4
Beijing 3
Bologna 3
Busto Arsizio 3
Council Bluffs 3
Magnago 3
Melbourne 3
Xi'an 3
Bergamo 2
Como 2
Dallas 2
Gatchina 2
Hangzhou 2
Kassel 2
Kunming 2
Kwai Chung 2
Las Vegas 2
Seattle 2
Segrate 2
Shijiazhuang 2
Bacoor 1
Bari 1
Bloemfontein 1
Borås 1
Changzhi 1
Changzhou 1
Dongyang 1
Espoo 1
Foshan 1
Frankfurt am Main 1
Hefei 1
Houston 1
Jiaxing 1
Lansing 1
Lappeenranta 1
London 1
Lübeck 1
Manila 1
Nanjing 1
Omsk 1
Rabat 1
Redwood City 1
Rockville 1
San Diego 1
San Francisco 1
St Petersburg 1
São Paulo 1
Taizhou 1
Vimodrone 1
Volgograd 1
Totale 491
Salva come PNG Salva come JPEG
Nome #
Cell-to-cell spread-blocking activity is extremely limited in the sera of HSV-1 and HSV-2 infected subjects 38
Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine 35
Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy 32
Alternative methods of vaccine delivery: An overview of edible and intradermal vaccines 31
Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19 29
JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes? 27
Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge 27
A Human Stem Cell-Derived Neurosensory–Epithelial Circuitry on a Chip to Model Herpes Simplex Virus Reactivation 26
Bacteriophages and Their Immunological Applications against Infectious Threats 26
Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro 25
Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. 24
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models 23
Characterization of two human monoclonal anti-E2/HCV antibodies for potential application in prevention and treatment of HCV infection 23
Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols 23
Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes 23
Evaluation of synergistic interactions of anti-HCV/E2 monoclonal antibodies 23
Nanopore ReCappable sequencing maps SARS-CoV-2 5' capping sites and provides new insights into the structure of sgRNAs 22
Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects 21
Viral Respiratory Pathogens and Lung Injury 21
The interferon landscape along the respiratory tract impacts the severity of COVID-19 21
Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects 21
The initial interplay between HIV and mucosal innate immunity 20
HUMAN MONOCLONAL ANTIBODY ENDOWED WITH ANTI-HSV-1 AND -2 ACTIVITY STRONGLY INHIBITS VIRUS REPLICATION 20
Interferon-β 1a inhibits SARS-CoV-2 in vitro when administered after virus infection 20
Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials 20
Broadly neutralizing human monoclonal antibodies: a novel resource against influenza viruses 20
Circulating SARS-CoV-2 variants in Italy, October 2020–March 2021 20
Smallpox vaccination-elicited antibodies cross-neutralize 2022-Monkeypox virus Clade II 19
Neutralization Interfering Antibodies: a "Novel" Mechanism of Humoral Immune Mutiny and Viral Evasion? 19
IN VIVO PROTECTION CONFERRED BY HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST HSV-1 AND 2 19
Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2 18
Influenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines 18
Epitope mapping by epitope excision, hydrogen/deuterium exchange, and peptide-panning techniques combined with in silico analysis 18
Characterization of a lineage c.36 sars-cov-2 isolate with reduced susceptibility to neutralization circulating in lombardy, italy 17
Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection 17
Phage Therapy: An Alternative to Antibiotics 15
Peptide-based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by monoclonal antibodies and the identification of T-cell-activating peptides. 15
Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle 15
Role and potential therapeutic use of antibodies against herpetic infections 15
Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro 15
Molecular characterization of the human neutralizing response against hepatitis C virus and its role in the prediction of the infection outcome 15
Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases 14
Next Generation Vaccines for Infectious Diseases 14
Synergistic neutralization of HCV by two broadly neutralizing human monoclonal antibodies 14
Unveiling the role of PUS7-mediated pseudouridylation in host protein interactions specific for the SARS-CoV-2 RNA genome 13
A spatial multi-scale fluorescence microscopy toolbox discloses entry checkpoints of SARS-CoV-2 variants in Vero E6 cells 12
IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19 12
Editorial: Viral escape of mucosal immunity in sexually transmitted diseases 11
Natural Flavonoid Derivatives Have Pan-Coronavirus Antiviral Activity 11
null 1
Totale 998
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.684
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.684
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207 0 0 0 0 0 0 6 0 0 0 0 1
2020/202113 2 0 0 2 4 0 2 0 0 3 0 0
2021/202284 6 3 10 10 13 7 9 2 2 9 0 13
2022/2023356 89 78 49 7 3 41 33 30 15 2 8 1
2023/2024315 1 20 42 62 19 62 9 25 13 8 18 36
2024/2025175 81 20 13 35 26 0 0 0 0 0 0 0
Totale 998